Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia

Pediatr Infect Dis J. 2009 May;28(5):445-7. doi: 10.1097/INF.0b013e3181927891.

Abstract

Daptomycin is a Food and Drug Administration-approved alternative to vancomycin for the treatment of serious methicillin-resistant Staphylococcus aureus infections in adults. Treatment failure with daptomycin is increasingly reported in adults, but data in children are limited. We report an adolescent patient with severe burn injuries who had persistent methicillin-resistant Staphylococcus aureus bacteremia and rapidly developed nonsusceptibility to daptomycin. We review the relevant literature.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteremia / drug therapy
  • Bacteremia / microbiology
  • Daptomycin / therapeutic use*
  • Drug Therapy, Combination
  • Gentamicins / administration & dosage
  • Gentamicins / therapeutic use
  • Humans
  • Male
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Microbial Sensitivity Tests
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / microbiology*
  • Vancomycin / administration & dosage
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Gentamicins
  • Vancomycin
  • Daptomycin